个人中心 - 老虎社区

ReneeLevin3

IP属地：未知

帖子 · 6帖子 · 6
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- ReneeLevin3ReneeLevin3
  ·2021-12-24
  Good!
  Tesla shares rose nearly 2% in early trading<blockquote>特斯拉股价早盘上涨近2%</blockquote>
  Tesla shares rose nearly 2% in early trading.A day after saying he had “sold enough” to meet his goa
  Tesla shares rose nearly 2% in early trading<blockquote>特斯拉股价早盘上涨近2%</blockquote>
  1,758 评论
  3
  分享
  举报
- ReneeLevin3ReneeLevin3
  ·2021-12-24
  Ok
  U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸作为第二种易于使用的抗COVID-19药物</blockquote>
  U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another ea
  U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸作为第二种易于使用的抗COVID-19药物</blockquote>
  3,507 2
  12
  分享
  举报
- ReneeLevin3ReneeLevin3
  ·2021-12-18
  I didn't manage to get grab at 6.80[Cry]
  2,569 评论
  点赞
  分享
  举报
- ReneeLevin3ReneeLevin3
  ·2021-12-18
  Buy n wait
  U.S. stocks sink at Friday's open,Nasdaq Composite Index declines 0.9%<blockquote>美股周五开盘下跌，纳斯达克综合指数下跌0.9%</blockquote>
  U.S. stocks sink at Friday's open as 10-year Treasury yield falls below 1.4% to cap Fed week,Nasdaq
  U.S. stocks sink at Friday's open,Nasdaq Composite Index declines 0.9%<blockquote>美股周五开盘下跌，纳斯达克综合指数下跌0.9%</blockquote>
  1,827 评论
  3
  分享
  举报
- ReneeLevin3ReneeLevin3
  ·2021-12-15
  Great ariticle, would you like to share it?
  GRAB Stock: What to Know About the Acquisition Putting Grab in the Spotlight<blockquote>Grab股票：关于让Grab成为焦点的收购需要了解什么</blockquote>
  Grab (NASDAQ:GRAB) made its debut on the Nasdaq on Dec. 2 after merging with Altimeter Growth Corp.,
  GRAB Stock: What to Know About the Acquisition Putting Grab in the Spotlight<blockquote>Grab股票：关于让Grab成为焦点的收购需要了解什么</blockquote>
  2,786 评论
  1
  分享
  举报
- ReneeLevin3ReneeLevin3
  ·2021-12-07
  Buy
  非常抱歉，此主贴已删除
  1,629 评论
  1
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4101624189408170","uuid":"4101624189408170","gmtCreate":1638709291072,"gmtModify":1638842157529,"name":"ReneeLevin3","pinyin":"reneelevin3","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/abe950888dd3ddea695a65a16d9782cb","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":16,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.04.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":698969980,"gmtCreate":1640276849978,"gmtModify":1640277047547,"author":{"id":"4101624189408170","authorId":"4101624189408170","name":"ReneeLevin3","avatar":"https://static.tigerbbs.com/abe950888dd3ddea695a65a16d9782cb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4101624189408170","idStr":"4101624189408170"},"themes":[],"htmlText":"Good!","listText":"Good!","text":"Good!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698969980","repostId":"1109764882","repostType":4,"repost":{"id":"1109764882","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640273505,"share":"https://www.laohu8.com/m/news/1109764882?lang=zh_CN&edition=full","pubTime":"2021-12-23 23:31","market":"us","language":"en","title":"Tesla shares rose nearly 2% in early trading<blockquote>特斯拉股价早盘上涨近2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109764882","media":"Tiger Newspress","summary":"Tesla shares rose nearly 2% in early trading.A day after saying he had “sold enough” to meet his goa","content":"<p>Tesla&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/2503c828d8b377eafa4087febd8581d6\" tg-width=\"709\" tg-height=\"601\" width=\"100%\" height=\"auto\">A day after saying he had “sold enough” to meet his goal of selling 10% of his Tesla Inc. stake, Chief Executive Elon Musk on Wednesday tweeted that he’s “almost done,” and disclosed in filings with the Securities and Exchange Commission that he has exercised more stock options and sold another 934,000 shares, worth about $928.6 million.</p><p><blockquote>特斯拉股价早盘上涨近2%。在表示他已经“出售了足够的股份”以实现出售特斯拉公司10%股份的目标后一天，首席执行官Elon Musk周三在推特上表示，他“几乎完成了”，并在提交给美国证券交易委员会的文件中披露，他已经行使了更多股票期权，并另外出售了934,000股股票，价值约9.286亿美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla shares rose nearly 2% in early trading<blockquote>特斯拉股价早盘上涨近2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla shares rose nearly 2% in early trading<blockquote>特斯拉股价早盘上涨近2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-23 23:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Tesla&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/2503c828d8b377eafa4087febd8581d6\" tg-width=\"709\" tg-height=\"601\" width=\"100%\" height=\"auto\">A day after saying he had “sold enough” to meet his goal of selling 10% of his Tesla Inc. stake, Chief Executive Elon Musk on Wednesday tweeted that he’s “almost done,” and disclosed in filings with the Securities and Exchange Commission that he has exercised more stock options and sold another 934,000 shares, worth about $928.6 million.</p><p><blockquote>特斯拉股价早盘上涨近2%。在表示他已经“出售了足够的股份”以实现出售特斯拉公司10%股份的目标后一天，首席执行官Elon Musk周三在推特上表示，他“几乎完成了”，并在提交给美国证券交易委员会的文件中披露，他已经行使了更多股票期权，并另外出售了934,000股股票，价值约9.286亿美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109764882","content_text":"Tesla shares rose nearly 2% in early trading.A day after saying he had “sold enough” to meet his goal of selling 10% of his Tesla Inc. stake, Chief Executive Elon Musk on Wednesday tweeted that he’s “almost done,” and disclosed in filings with the Securities and Exchange Commission that he has exercised more stock options and sold another 934,000 shares, worth about $928.6 million.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":1758,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698960294,"gmtCreate":1640276821124,"gmtModify":1640276821124,"author":{"id":"4101624189408170","authorId":"4101624189408170","name":"ReneeLevin3","avatar":"https://static.tigerbbs.com/abe950888dd3ddea695a65a16d9782cb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4101624189408170","idStr":"4101624189408170"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698960294","repostId":"1192623075","repostType":4,"repost":{"id":"1192623075","kind":"news","pubTimestamp":1640269891,"share":"https://www.laohu8.com/m/news/1192623075?lang=zh_CN&edition=full","pubTime":"2021-12-23 22:31","market":"us","language":"en","title":"U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸作为第二种易于使用的抗COVID-19药物</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1192623075","media":"SeattleTimes","summary":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another ea","content":"<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.</p><p><blockquote>美国卫生监管机构周四批准了第二种针对COVID-19的药物，提供了另一种易于使用的药物来对抗不断上升的奥密克戎感染浪潮。</blockquote></p><p> The Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.</p><p><blockquote>美国食品和药物管理局批准默克公司的molnupiravir的一天前，该机构批准了辉瑞公司的一种竞争药物。这种名为Paxlovid的药物很可能成为针对该病毒的首选治疗方法，因为它具有优越的益处和较温和的副作用。</blockquote></p><p> As a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.</p><p><blockquote>因此，默克公司的药物预计对疫情的作用将比几周前预测的要小。它阻止严重新冠肺炎的能力比最初宣布的要小得多，药物标签将警告严重的安全问题，包括潜在的出生缺陷。</blockquote></p><p> The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.</p><p><blockquote>美国食品和药物管理局批准默克公司的药物用于患有COVID-19早期症状且住院风险最高的成年人，包括老年人以及患有肥胖症和心脏病等疾病的人。英国于11月初首次批准了该药物。</blockquote></p><p> Known as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.</p><p><blockquote>默克公司的这种药物被称为molnupiravir，将带有禁止在怀孕期间使用的警告。FDA表示，育龄妇女应在治疗期间和治疗后几天内采取避孕措施，而男性应在最后一次给药后至少三个月内采取避孕措施。</blockquote></p><p> The restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.</p><p><blockquote>FDA顾问小组上个月仅以微弱优势批准了该药物，并警告称其使用必须严格针对能够受益最大的患者，因此这些限制是意料之中的。</blockquote></p><p> The Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.</p><p><blockquote>辉瑞药丸的作用方式不同，也没有同样的风险。此外，辉瑞的药物在测试中的有效性大约是三倍，将高危患者的住院和死亡人数减少了近90%，而默克的药物减少了30%。</blockquote></p><p> Some experts question whether there will be much of a role for the Merck drug in the U.S.</p><p><blockquote>一些专家质疑默克公司的药物在美国是否会发挥很大作用。</blockquote></p><p> “To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”</p><p><blockquote>梅奥诊所的格雷戈里·波兰博士在谈到默克公司的药物时说：“如果辉瑞公司的药物供应充足，我认为它不会被使用。”“没有理由，因为它的功效较低且副作用风险较高。”</blockquote></p><p> For now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.</p><p><blockquote>目前，FDA的决定为对抗已导致超过80万美国人死亡的病毒提供了另一种潜在选择，尽管卫生官员正在为奥密克戎变种导致的创纪录病例、住院和死亡做好准备。包括默克公司在内的抗病毒药物预计对奥密克戎病毒有效，因为它们不针对该变种大多数令人担忧的突变所在的刺突蛋白。</blockquote></p><p> The FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.</p><p><blockquote>FDA的决定是基于结果显示，近7%服用该药物的患者最终住院，其中一人在30天后死亡。相比之下，服用安慰剂的住院患者比例为10%，死亡人数为9人。</blockquote></p><p> Federal officials have agreed to purchase enough of the drug to treat 3.1 million people.</p><p><blockquote>联邦官员已同意购买足够治疗310万人的药物。</blockquote></p><p> The U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.</p><p><blockquote>美国将为默克公司的每个疗程支付约700美元，该疗程要求患者每天两次服用四粒药丸，持续五天。哈佛大学和伦敦国王学院的一项审查估计，每个40粒药丸的疗程费用约为18美元。</blockquote></p><p> Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.</p><p><blockquote>默克公司的药物在冠状病毒的遗传密码中插入微小错误，以减缓其繁殖。这种遗传效应引发了人们的担忧，即该药物可能会导致人类胎儿发生突变，甚至刺激更强的病毒株。但FDA科学家表示，变异风险很大程度上是理论上的，因为人们服用这种药物的时间很短。</blockquote></p><p></p>","source":"lsy1640271591192","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸作为第二种易于使用的抗COVID-19药物</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸作为第二种易于使用的抗COVID-19药物</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">SeattleTimes</strong><span class=\"h-time small\">2021-12-23 22:31</span>\n</p>\n</h4>\n</header>\n<article>\n<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.</p><p><blockquote>美国卫生监管机构周四批准了第二种针对COVID-19的药物，提供了另一种易于使用的药物来对抗不断上升的奥密克戎感染浪潮。</blockquote></p><p> The Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.</p><p><blockquote>美国食品和药物管理局批准默克公司的molnupiravir的一天前，该机构批准了辉瑞公司的一种竞争药物。这种名为Paxlovid的药物很可能成为针对该病毒的首选治疗方法，因为它具有优越的益处和较温和的副作用。</blockquote></p><p> As a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.</p><p><blockquote>因此，默克公司的药物预计对疫情的作用将比几周前预测的要小。它阻止严重新冠肺炎的能力比最初宣布的要小得多，药物标签将警告严重的安全问题，包括潜在的出生缺陷。</blockquote></p><p> The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.</p><p><blockquote>美国食品和药物管理局批准默克公司的药物用于患有COVID-19早期症状且住院风险最高的成年人，包括老年人以及患有肥胖症和心脏病等疾病的人。英国于11月初首次批准了该药物。</blockquote></p><p> Known as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.</p><p><blockquote>默克公司的这种药物被称为molnupiravir，将带有禁止在怀孕期间使用的警告。FDA表示，育龄妇女应在治疗期间和治疗后几天内采取避孕措施，而男性应在最后一次给药后至少三个月内采取避孕措施。</blockquote></p><p> The restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.</p><p><blockquote>FDA顾问小组上个月仅以微弱优势批准了该药物，并警告称其使用必须严格针对能够受益最大的患者，因此这些限制是意料之中的。</blockquote></p><p> The Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.</p><p><blockquote>辉瑞药丸的作用方式不同，也没有同样的风险。此外，辉瑞的药物在测试中的有效性大约是三倍，将高危患者的住院和死亡人数减少了近90%，而默克的药物减少了30%。</blockquote></p><p> Some experts question whether there will be much of a role for the Merck drug in the U.S.</p><p><blockquote>一些专家质疑默克公司的药物在美国是否会发挥很大作用。</blockquote></p><p> “To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”</p><p><blockquote>梅奥诊所的格雷戈里·波兰博士在谈到默克公司的药物时说：“如果辉瑞公司的药物供应充足，我认为它不会被使用。”“没有理由，因为它的功效较低且副作用风险较高。”</blockquote></p><p> For now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.</p><p><blockquote>目前，FDA的决定为对抗已导致超过80万美国人死亡的病毒提供了另一种潜在选择，尽管卫生官员正在为奥密克戎变种导致的创纪录病例、住院和死亡做好准备。包括默克公司在内的抗病毒药物预计对奥密克戎病毒有效，因为它们不针对该变种大多数令人担忧的突变所在的刺突蛋白。</blockquote></p><p> The FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.</p><p><blockquote>FDA的决定是基于结果显示，近7%服用该药物的患者最终住院，其中一人在30天后死亡。相比之下，服用安慰剂的住院患者比例为10%，死亡人数为9人。</blockquote></p><p> Federal officials have agreed to purchase enough of the drug to treat 3.1 million people.</p><p><blockquote>联邦官员已同意购买足够治疗310万人的药物。</blockquote></p><p> The U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.</p><p><blockquote>美国将为默克公司的每个疗程支付约700美元，该疗程要求患者每天两次服用四粒药丸，持续五天。哈佛大学和伦敦国王学院的一项审查估计，每个40粒药丸的疗程费用约为18美元。</blockquote></p><p> Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.</p><p><blockquote>默克公司的药物在冠状病毒的遗传密码中插入微小错误，以减缓其繁殖。这种遗传效应引发了人们的担忧，即该药物可能会导致人类胎儿发生突变，甚至刺激更强的病毒株。但FDA科学家表示，变异风险很大程度上是理论上的，因为人们服用这种药物的时间很短。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/\">SeattleTimes</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRK":"默沙东"},"source_url":"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192623075","content_text":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.\nThe Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.\nAs a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.\nThe Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.\nKnown as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.\nThe restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.\nThe Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.\nSome experts question whether there will be much of a role for the Merck drug in the U.S.\n“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”\nFor now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.\nThe FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.\nFederal officials have agreed to purchase enough of the drug to treat 3.1 million people.\nThe U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.\nMerck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.","news_type":1,"symbols_score_info":{"MRK":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3507,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699637825,"gmtCreate":1639790490780,"gmtModify":1639790493389,"author":{"id":"4101624189408170","authorId":"4101624189408170","name":"ReneeLevin3","avatar":"https://static.tigerbbs.com/abe950888dd3ddea695a65a16d9782cb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4101624189408170","idStr":"4101624189408170"},"themes":[],"htmlText":"I didn't manage to get grab at 6.80[Cry]&nbsp;","listText":"I didn't manage to get grab at 6.80[Cry]&nbsp;","text":"I didn't manage to get grab at 6.80[Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699637825","isVote":1,"tweetType":1,"viewCount":2569,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699631927,"gmtCreate":1639789699767,"gmtModify":1639789699767,"author":{"id":"4101624189408170","authorId":"4101624189408170","name":"ReneeLevin3","avatar":"https://static.tigerbbs.com/abe950888dd3ddea695a65a16d9782cb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4101624189408170","idStr":"4101624189408170"},"themes":[],"htmlText":"Buy n wait","listText":"Buy n wait","text":"Buy n wait","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699631927","repostId":"1114105828","repostType":4,"repost":{"id":"1114105828","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639751560,"share":"https://www.laohu8.com/m/news/1114105828?lang=zh_CN&edition=full","pubTime":"2021-12-17 22:32","market":"us","language":"en","title":"U.S. stocks sink at Friday's open,Nasdaq Composite Index declines 0.9%<blockquote>美股周五开盘下跌，纳斯达克综合指数下跌0.9%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1114105828","media":"Tiger Newspress","summary":"U.S. stocks sink at Friday's open as 10-year Treasury yield falls below 1.4% to cap Fed week,Nasdaq ","content":"<p>U.S. stocks sink at Friday's open as 10-year Treasury yield falls below 1.4% to cap Fed week,Nasdaq Composite Index declines 0.9%,Dow trades 0.5% lower; S&amp;P 500 down 0.6%.</p><p><blockquote>美国股市周五开盘下跌，10年期国债收益率跌破1.4%，限制美联储一周，纳斯达克综合指数下跌0.9%，道指下跌0.5%；标普500下跌0.6%。</blockquote></p><p> Shares of FedEx (FDX) jumped after the shipping giant raised its full-year earnings forecast, delivered better-than-expected fiscal second-quarter results and authorized a new $5 billion stock buyback program. Rivian (RIVN), meanwhile, saw shares sink following its first quarterly report since its IPO last month. The electric-vehicle makersaid in its shareholder letterit expected to be \"a few hundred vehicles short\" of its prior target of producing 1,200 units by the end of this year.</p><p><blockquote>航运巨头联邦快递(FDX)上调了全年盈利预期，公布了好于预期的第二财季业绩，并授权了一项新的50亿美元股票回购计划，该公司股价上涨。与此同时，Rivian(RIVN)在发布自上个月首次公开募股以来的第一份季度报告后股价下跌。这家电动汽车制造商在股东信中表示，预计到今年年底生产1,200辆汽车的目标“还差几百辆”。</blockquote></p><p> Investors' main focus this week has remained fixed on the Federal Reserve's updated outlook on monetary policy for next year, with the central bank's projections delivered mid-week suggesting the Fedcould hike interest rates three times next year.</p><p><blockquote>投资者本周的主要焦点仍然集中在美联储对明年货币政策的最新展望上，央行周中发布的预测表明美联储明年可能加息三次。</blockquote></p><p> The specter of higher rates — and a lower-liquidity environment as the central bank also speeds up the tapering process of its asset purchases — has continued to weigh heavily on longer-duration technology and growth stocks valued heavily on future earnings potential. The Nasdaq Composite has fallen by 5% over the past month through Thursday's close. And shares of some notable technology stocks extended declines on Friday, with Apple (AAPL) shares dropping by more than 1% in early trading after a nearly 4% decrease on Thursday.</p><p><blockquote>利率上升的幽灵——以及随着央行也加快缩减资产购买进程而导致的流动性下降——继续给长期科技股和成长型股票带来沉重压力，这些股票对未来盈利潜力的估值很高。截至周四收盘，纳斯达克综合指数在过去一个月下跌了5%。一些著名科技股的股价周五延续跌势，苹果(AAPL)股价继周四下跌近4%后，早盘下跌超过1%。</blockquote></p><p> On the other hand, cyclical stocks in the energy and financials sectors outperformed on Thursday, with the prospects of higher interest rates and stronger growth seen as benefitting these sectors.</p><p><blockquote>另一方面，能源和金融板块的周期性股票周四表现出色，利率上升和增长强劲的前景被视为有利于这些板块。</blockquote></p><p> \"The thing investors have to understand is, we're going through a major transition in monetary policy,\" Troy Gayeski, FS Investments chief market strategist,told Yahoo Finance Live on Thursday.\"The Fed has been running emergency policies arguably far longer than they should have been, and as that money supply growth slows down as they ease off the balance sheet expansion and ultimately hike next year, one would at least expect more volatility in markets. And that's really what we've been seeing the last month.\"</p><p><blockquote>FS Investments首席市场策略师特洛伊·盖耶斯基(Troy Gayeski)周四对雅虎财经直播表示：“投资者必须明白的是，我们正在经历货币政策的重大转变。”“美联储实施紧急政策的时间可以说比应有的时间长得多，随着货币供应增长放缓，随着他们放松资产负债表扩张并最终在明年加息，人们至少预计市场会出现更多波动。这确实是我们上个月看到的情况。”</blockquote></p><p> \"The biggest difference between now and six months ago, or even more than a year ago, is you could pretty much go long anything and you were confident it was going to go up. The economy was booming, we had a lot of fiscal stimulus, we still had unprecedented monetary policy stimulus,\" he added. \"And it's a very different environment in 2022 where you're going to have to pick and choose much more carefully.\"</p><p><blockquote>“现在与六个月前，甚至一年多前最大的区别是，你几乎可以做多任何东西，并且你有信心它会上涨。经济正在蓬勃发展，我们有很多财政刺激，我们仍然有前所未有的货币政策刺激，”他补充道。“2022年的环境非常不同，你必须更加仔细地挑选。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stocks sink at Friday's open,Nasdaq Composite Index declines 0.9%<blockquote>美股周五开盘下跌，纳斯达克综合指数下跌0.9%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stocks sink at Friday's open,Nasdaq Composite Index declines 0.9%<blockquote>美股周五开盘下跌，纳斯达克综合指数下跌0.9%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-17 22:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>U.S. stocks sink at Friday's open as 10-year Treasury yield falls below 1.4% to cap Fed week,Nasdaq Composite Index declines 0.9%,Dow trades 0.5% lower; S&amp;P 500 down 0.6%.</p><p><blockquote>美国股市周五开盘下跌，10年期国债收益率跌破1.4%，限制美联储一周，纳斯达克综合指数下跌0.9%，道指下跌0.5%；标普500下跌0.6%。</blockquote></p><p> Shares of FedEx (FDX) jumped after the shipping giant raised its full-year earnings forecast, delivered better-than-expected fiscal second-quarter results and authorized a new $5 billion stock buyback program. Rivian (RIVN), meanwhile, saw shares sink following its first quarterly report since its IPO last month. The electric-vehicle makersaid in its shareholder letterit expected to be \"a few hundred vehicles short\" of its prior target of producing 1,200 units by the end of this year.</p><p><blockquote>航运巨头联邦快递(FDX)上调了全年盈利预期，公布了好于预期的第二财季业绩，并授权了一项新的50亿美元股票回购计划，该公司股价上涨。与此同时，Rivian(RIVN)在发布自上个月首次公开募股以来的第一份季度报告后股价下跌。这家电动汽车制造商在股东信中表示，预计到今年年底生产1,200辆汽车的目标“还差几百辆”。</blockquote></p><p> Investors' main focus this week has remained fixed on the Federal Reserve's updated outlook on monetary policy for next year, with the central bank's projections delivered mid-week suggesting the Fedcould hike interest rates three times next year.</p><p><blockquote>投资者本周的主要焦点仍然集中在美联储对明年货币政策的最新展望上，央行周中发布的预测表明美联储明年可能加息三次。</blockquote></p><p> The specter of higher rates — and a lower-liquidity environment as the central bank also speeds up the tapering process of its asset purchases — has continued to weigh heavily on longer-duration technology and growth stocks valued heavily on future earnings potential. The Nasdaq Composite has fallen by 5% over the past month through Thursday's close. And shares of some notable technology stocks extended declines on Friday, with Apple (AAPL) shares dropping by more than 1% in early trading after a nearly 4% decrease on Thursday.</p><p><blockquote>利率上升的幽灵——以及随着央行也加快缩减资产购买进程而导致的流动性下降——继续给长期科技股和成长型股票带来沉重压力，这些股票对未来盈利潜力的估值很高。截至周四收盘，纳斯达克综合指数在过去一个月下跌了5%。一些著名科技股的股价周五延续跌势，苹果(AAPL)股价继周四下跌近4%后，早盘下跌超过1%。</blockquote></p><p> On the other hand, cyclical stocks in the energy and financials sectors outperformed on Thursday, with the prospects of higher interest rates and stronger growth seen as benefitting these sectors.</p><p><blockquote>另一方面，能源和金融板块的周期性股票周四表现出色，利率上升和增长强劲的前景被视为有利于这些板块。</blockquote></p><p> \"The thing investors have to understand is, we're going through a major transition in monetary policy,\" Troy Gayeski, FS Investments chief market strategist,told Yahoo Finance Live on Thursday.\"The Fed has been running emergency policies arguably far longer than they should have been, and as that money supply growth slows down as they ease off the balance sheet expansion and ultimately hike next year, one would at least expect more volatility in markets. And that's really what we've been seeing the last month.\"</p><p><blockquote>FS Investments首席市场策略师特洛伊·盖耶斯基(Troy Gayeski)周四对雅虎财经直播表示：“投资者必须明白的是，我们正在经历货币政策的重大转变。”“美联储实施紧急政策的时间可以说比应有的时间长得多，随着货币供应增长放缓，随着他们放松资产负债表扩张并最终在明年加息，人们至少预计市场会出现更多波动。这确实是我们上个月看到的情况。”</blockquote></p><p> \"The biggest difference between now and six months ago, or even more than a year ago, is you could pretty much go long anything and you were confident it was going to go up. The economy was booming, we had a lot of fiscal stimulus, we still had unprecedented monetary policy stimulus,\" he added. \"And it's a very different environment in 2022 where you're going to have to pick and choose much more carefully.\"</p><p><blockquote>“现在与六个月前，甚至一年多前最大的区别是，你几乎可以做多任何东西，并且你有信心它会上涨。经济正在蓬勃发展，我们有很多财政刺激，我们仍然有前所未有的货币政策刺激，”他补充道。“2022年的环境非常不同，你必须更加仔细地挑选。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114105828","content_text":"U.S. stocks sink at Friday's open as 10-year Treasury yield falls below 1.4% to cap Fed week,Nasdaq Composite Index declines 0.9%,Dow trades 0.5% lower; S&P 500 down 0.6%.\nShares of FedEx (FDX) jumped after the shipping giant raised its full-year earnings forecast, delivered better-than-expected fiscal second-quarter results and authorized a new $5 billion stock buyback program. Rivian (RIVN), meanwhile, saw shares sink following its first quarterly report since its IPO last month. The electric-vehicle makersaid in its shareholder letterit expected to be \"a few hundred vehicles short\" of its prior target of producing 1,200 units by the end of this year.\nInvestors' main focus this week has remained fixed on the Federal Reserve's updated outlook on monetary policy for next year, with the central bank's projections delivered mid-week suggesting the Fedcould hike interest rates three times next year.\nThe specter of higher rates — and a lower-liquidity environment as the central bank also speeds up the tapering process of its asset purchases — has continued to weigh heavily on longer-duration technology and growth stocks valued heavily on future earnings potential. The Nasdaq Composite has fallen by 5% over the past month through Thursday's close. And shares of some notable technology stocks extended declines on Friday, with Apple (AAPL) shares dropping by more than 1% in early trading after a nearly 4% decrease on Thursday.\nOn the other hand, cyclical stocks in the energy and financials sectors outperformed on Thursday, with the prospects of higher interest rates and stronger growth seen as benefitting these sectors.\n\"The thing investors have to understand is, we're going through a major transition in monetary policy,\" Troy Gayeski, FS Investments chief market strategist,told Yahoo Finance Live on Thursday.\"The Fed has been running emergency policies arguably far longer than they should have been, and as that money supply growth slows down as they ease off the balance sheet expansion and ultimately hike next year, one would at least expect more volatility in markets. And that's really what we've been seeing the last month.\"\n\"The biggest difference between now and six months ago, or even more than a year ago, is you could pretty much go long anything and you were confident it was going to go up. The economy was booming, we had a lot of fiscal stimulus, we still had unprecedented monetary policy stimulus,\" he added. \"And it's a very different environment in 2022 where you're going to have to pick and choose much more carefully.\"","news_type":1,"symbols_score_info":{".IXIC":0.9,".DJI":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":1827,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607621854,"gmtCreate":1639534716766,"gmtModify":1639534716766,"author":{"id":"4101624189408170","authorId":"4101624189408170","name":"ReneeLevin3","avatar":"https://static.tigerbbs.com/abe950888dd3ddea695a65a16d9782cb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4101624189408170","idStr":"4101624189408170"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607621854","repostId":"1159300602","repostType":2,"repost":{"id":"1159300602","kind":"news","pubTimestamp":1639529768,"share":"https://www.laohu8.com/m/news/1159300602?lang=zh_CN&edition=full","pubTime":"2021-12-15 08:56","market":"us","language":"en","title":"GRAB Stock: What to Know About the Acquisition Putting Grab in the Spotlight<blockquote>Grab股票：关于让Grab成为焦点的收购需要了解什么</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1159300602","media":"investor place","summary":"Grab (NASDAQ:GRAB) made its debut on the Nasdaq on Dec. 2 after merging with Altimeter Growth Corp.,","content":"<p><div> Grab (NASDAQ:GRAB) made its debut on the Nasdaq on Dec. 2 after merging with Altimeter Growth Corp., a special purpose acquisition company (SPAC) managed by hedge fund Altimeter Capital. However, the ...</p><p><blockquote><div>Grab（纳斯达克：GRAB）与对冲基金Altimeter Capital管理的特殊目的收购公司（SPAC）Altimeter Growth Corp.合并后，于12月2日在纳斯达克首次亮相。然而，...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/grab-stock-what-to-know-about-the-acquisition-putting-grab-in-the-spotlight-today/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/grab-stock-what-to-know-about-the-acquisition-putting-grab-in-the-spotlight-today/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GRAB Stock: What to Know About the Acquisition Putting Grab in the Spotlight<blockquote>Grab股票：关于让Grab成为焦点的收购需要了解什么</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGRAB Stock: What to Know About the Acquisition Putting Grab in the Spotlight<blockquote>Grab股票：关于让Grab成为焦点的收购需要了解什么</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">investor place</strong><span class=\"h-time small\">2021-12-15 08:56</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Grab (NASDAQ:GRAB) made its debut on the Nasdaq on Dec. 2 after merging with Altimeter Growth Corp., a special purpose acquisition company (SPAC) managed by hedge fund Altimeter Capital. However, the ...</p><p><blockquote><div>Grab（纳斯达克：GRAB）与对冲基金Altimeter Capital管理的特殊目的收购公司（SPAC）Altimeter Growth Corp.合并后，于12月2日在纳斯达克首次亮相。然而，...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/grab-stock-what-to-know-about-the-acquisition-putting-grab-in-the-spotlight-today/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/grab-stock-what-to-know-about-the-acquisition-putting-grab-in-the-spotlight-today/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/grab-stock-what-to-know-about-the-acquisition-putting-grab-in-the-spotlight-today/\">investor place</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"source_url":"https://investorplace.com/2021/12/grab-stock-what-to-know-about-the-acquisition-putting-grab-in-the-spotlight-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159300602","content_text":"Grab (NASDAQ:GRAB) made its debut on the Nasdaq on Dec. 2 after merging with Altimeter Growth Corp., a special purpose acquisition company (SPAC) managed by hedge fund Altimeter Capital. However, the ride-hailing and delivery company has experienced a rocky start, as shares of GRAB stock have declined more than 25% since. Shares are rocketing even lower today after Grab announced a major acquisition. The transaction is the largest acquisition for Grab since it acquired Ovo, an Indonesian wallet provider, earlier this year.\nSo, what is the big acquisition news?\nToday, Grab announced that it would be buying Jaya Grocer, one of the top premium supermarket chains based in Malaysia. Financial terms of the acquisition were not immediately disclosed, although a source close to the matter said the acquisition price would be between RM 1.5 billion and RM 1.8 billion. As part of the agreement, Grab will buy 100% of all Jaya Grocer ordinary shares and 75% of its preference shares. Additionally, Grab will have the option to buy the remaining preference shares after the transaction closes. Preference shareholders have priority over common stock holders when it comes to dividends, although they do not generally have voting rights.\nFurthermore, due to regulatory reasons, Grab plans to partner with a local investor, who will own 50% of the voting shares in Jaya Grocer. However, the local investor has not been disclosed yet. Grab announced that the acquisition will likely close during the first quarter of 2022.\nThe grocery chain reported RM 1.34 billion in sales for the financial year ended June 2020. Gross profit tallied in at RM 68.65 million.\nJaya Grocer has been on sale for over a year, previously rejecting offers from The Carlyle Group and CVC Capital Partners. The grocer is reportedly seeking at least RM 1.1 billion.\nFurthermore, less than a month ago, the Teng family, who founded Jaya Grocer, announced that they were buying back a 45% stake in Jaya Grocer from private equity firm AIGF Advisors for RM 411 million. AIGF Advisors first purchased its stake of Jaya Grocer in 2016 for RM 300 million. The Teng family stands to make a profit after Grab’s recent acquisition.\nShares of Grab are trading down more than 10% on the day. As a general reminder, when an acquisition occurs, the acquirer’s stock price usually goes down. However, the company getting acquired usually sees an increase in price. This is because the acquirer is using assets to satisfy the transaction, which negatively impacts the balance sheet in the short term.","news_type":1,"symbols_score_info":{"GRAB":0.9}},"isVote":1,"tweetType":1,"viewCount":2786,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606194289,"gmtCreate":1638840973023,"gmtModify":1638842630717,"author":{"id":"4101624189408170","authorId":"4101624189408170","name":"ReneeLevin3","avatar":"https://static.tigerbbs.com/abe950888dd3ddea695a65a16d9782cb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4101624189408170","idStr":"4101624189408170"},"themes":[],"htmlText":"Buy&nbsp;","listText":"Buy&nbsp;","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606194289","repostId":"2189685687","repostType":4,"isVote":1,"tweetType":1,"viewCount":1629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}